TY - JOUR
T1 - Oral Antivirals for Chronic Hepatitis B
AU - Min, Albert D.
AU - Dienstag, Jules L.
PY - 2007/11
Y1 - 2007/11
N2 - Four oral antiviral agents have been approved by the United States Food and Drug Administration (FDA) for the treatment of chronic hepatitis B: lamivudine, adefovir, entecavir, and telbivudine. This article reviews the durability of response, dose regimen, predictors of response, safety, and problems with resistance of these four agents and of promising agents currently in phase III clinical trials for the treatment of patients who have hepatitis B e antigen-positive and -negative chronic hepatitis B.
AB - Four oral antiviral agents have been approved by the United States Food and Drug Administration (FDA) for the treatment of chronic hepatitis B: lamivudine, adefovir, entecavir, and telbivudine. This article reviews the durability of response, dose regimen, predictors of response, safety, and problems with resistance of these four agents and of promising agents currently in phase III clinical trials for the treatment of patients who have hepatitis B e antigen-positive and -negative chronic hepatitis B.
UR - http://www.scopus.com/inward/record.url?scp=35548975086&partnerID=8YFLogxK
U2 - 10.1016/j.cld.2007.08.003
DO - 10.1016/j.cld.2007.08.003
M3 - Review article
C2 - 17981232
AN - SCOPUS:35548975086
SN - 1089-3261
VL - 11
SP - 851
EP - 868
JO - Clinics in Liver Disease
JF - Clinics in Liver Disease
IS - 4
ER -